Aripiprazole: Effectiveness and Safety Under Naturalistic Conditions

Experimental and Clinical Psychopharmacology

Volumn 15, Issue 6, 2007, Pages 569-575

  Di Lorenzo, Rosaria ^a   Amoretti, Alessandra ^a,b,c   Forghieri, Matilde ^a,b,c   Fiorini, Fiorenza ^a,b,c   Genedani, Susanna ^c   Rigatelli, Marco ^c  

^a AUSL Modena   (Italy)

^b Section of Pharmacology   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

aripiprazole; effectiveness; inpatients; naturalistic conditions; outpatients

Indexed keywords

ARIPIPRAZOLE;

ADULT; ANXIETY; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CONTROLLED STUDY; DELUSIONAL DISORDER; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HOSPITAL PATIENT; HUMAN; INSOMNIA; MALE; OUTPATIENT; PSYCHOSIS; RESTLESSNESS; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOIDISM; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; SIDE EFFECT; TREATMENT DURATION;

ADULT; ANTIPSYCHOTIC AGENTS; ANXIETY; FEMALE; HUMANS; INPATIENTS; ITALY; MALE; MIDDLE AGED; OUTPATIENTS; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; QUINOLONES; RECURRENCE; RETROSPECTIVE STUDIES; SCHIZOID PERSONALITY DISORDER; SCHIZOPHRENIA, PARANOID; SCHIZOTYPAL PERSONALITY DISORDER; SLEEP INITIATION AND MAINTENANCE DISORDERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 38549121374     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/1064-1297.15.6.569     Document Type: Article

References (46)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. (1980), Author, Washington, DC
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev. (2000), Author, Washington, DC
3. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. 2nd ed. (2004), Author, Arlington, VA
4. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., and Weinberger D.R. Remission in schizophrenia: Proposed criteria and rationale for consensus. American Journal of Psychiatry 162 (2005) 441-449
5. Baldessarini R.J., and Frankenburg F.R. Clozapine: A novel antipsychotic agent. New England Journal of Medicine 324 (1991) 746-754
6. 2 receptors. Journal of Pharmacology and Experimental Therapeutics 302 (2002) 381-389
7. Cannon M., and Jones P. Neuroepidemiology: Schizophrenia. Journal of Neurology, Neuropsychiatry and Neurosurgery 61 (1996) 604-613
8. Carr V.J. Recovery from schizophrenia: A review of patterns of psychosis. Schizophrenia Bulletin 9 (1983) 95-119
9. Casey D.E., Carson W.H., Saha A.R., Liebeskind A., Ali M.W., Jody D., et al. Switching patients to aripiprazole from other antipsychotic agents: A multicentric randomized study. Psychopharmacology 166 (2003) 391-399
10. Chrzanowski W.K., Marcus R.N., Torbeyns A., Nyilas M., and McQuade R.D. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: A 52-week, open-label comparison with olanzapine. Psychopharmacology 189 (2006) 259-266
11. Daniel D.G., Saha A.R., Ingenito G.G., Carson W.H., and Dunbar G. Aripiprazole, a novel antipsychotic: Overview of a phase II study result. International Journal of Neuropsychopharmacology 3 Suppl. 1 (2000) S157
12. DeLeon A., Patel N.C., and Crismon M.L. Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy and tolerability. Clinical Therapeutics 26 (2004) 649-666
13. Dixon L., and Lehman A. Family interventions for schizophrenia. Schizophrenia Bulletin 21 (1995) 567-578
14. Endicott J., Spitzer R.L., Fleiss J.L., and Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry 33 (1976) 766-771
15. Falloon I.R.H., Held T., Roncone R., Coverdale J.H., and Laidlaw T.M. Optimal treatment strategies to enhance recovery from schizophrenia. Australian and New Zealand Journal of Psychiatry 32 (1998) 43-49
16. Gerlach J. Atypical antipsychotics: An inspiring but confusing concept. Psychopharmacology 148 (2000) 1-2
17. Hegarty J.D., Baldessarini R.J., Tohen M., Waternaux C., and Oepen G. One hundred years of schizophrenia: A meta-analysis of the outcome literature. American Journal of Psychiatry 151 (1994) 1409-1416
18. Johnstone E.C. Schizophrenia: Problems in clinical practice. Lancet 341 (1993) 536-538
19. Jordan S., Koprivica V., Chen R., Tottori K., Kikuchi T., and Altar C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. European Journal of Pharmacology 441 (2002) 137-140
20. Kane J.M., Carson W.H., Saha A.R., McQuade R.D., Ingenito G.G., Zimbroff D.L., and Ali M.W. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry 63 (2002) 763-771
21. Kasper S., Lerman M.N., McQuade R.D., Saha A., Carson W.H., Ali M.W., et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. International Journal of Neuropsychopharmacology 6 (2003) 325-337
22. Keck P.E., Strakowski S.M., and McElroy S.L. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility and suicidality in patients with schizophrenia. Journal of Clinical Psychiatry 61 Suppl. 3 (2000) 4-9
23. Kessler R.C., Barker P.R., Colpe L.J., Epstein J.F., Gfroerer J.C., Hiripi E., et al. Screening for serious mental illness in the general population. Archives of General Psychiatry 60 (2003) 184-189
24. 2 receptor antagonistic activity. Journal of Pharmacology and Experimental Therapeutics 274 (1995) 329-336
25. Lehman A.F. Vocational rehabilitation in schizophrenia. Schizophrenia Bulletin 21 (1995) 645-656
26. Lehman A.F., Steinwachs D.M., and the Co-Investigators of the PORT Project. At issue: Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin 24 (1998) 1-10
27. Lehman A.F., Steinwachs D.M., and the Co-Investigators of the PORT Project. Patterns of usual care for schizophrenia: Initial results from the Schizophrenia Patient Outcomes Research Team (PORT) client survey. Schizophrenia Bulletin 24 (1998) 11-20
28. Lehman A.F., Ward N., and Linn L. Chronic mental patients: The quality of life issue. American Journal of Psychiatry 139 (1982) 1271-1276
29. Leucht S., Raymonde B., Kissling W., and Kane J.M. Early prediction of antipsychotic nonresponse among patients with schizophrenia. Journal of Clinical Psychiatry 68 (2007) 352-359
30. Lieberman J.A. Dopamine partial agonists. A new class of antipsychotic. CNS Drugs 18 (2004) 251-267
31. Marder S.R., McQuade R.D., Stock E., Kaplita S., Marcus R., Safferman A.Z., et al. Aripiprazole in the treatment of schizophrenia: Safety and tolerability in short-term, placebo-controlled trials. Schizophrenia Research 61 (2003) 123-136
32. McQuade R.D., Stock E., Marcus R., Jody D., Gharbia N.A., Vanveggel S., et al. A comparison of weight change during treatment with olanzapine or aripiprazole: Results from a randomized double-blind study. Journal of Clinical Psychiatry 65 Suppl. 18 (2004) 47-56
33. Overall I.E., and Gorham D.R. The Brief Psychiatric Rating Scale. Psychological Report 10 (1962) 799-812
34. Pigott T.A., Carson W.H., Saha A.R., Torbeyns A.F., Stock E.G., Ingenito G.G., and Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebo-controlled 26-week study. Journal of Clinical Psychiatry 64 (2003) 1048-1056
35. Potkin S.G., Saha A.R., Kujawa M.J., Carson W.H., Ali M.W., Stock E., et al. Aripiprazole, an antipsychotic with a novel mechanism of action and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 60 (2003) 681-690
36. Rice D.P., Kelman S., and Miller L.S. The economic burden of mental illness. Hospital Community Psychiatry 43 (1992) 1227-1232
37. Richelson E. Receptor pharmacology of neuroleptics: Relation to clinical effects. Journal of Clinical Psychiatry 60 (1999) 5-14
38. 2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. American Journal of Psychiatry 156 (1999) 876-884
39. Siegel S., and Castellan J.N. Nonparametric statistics for the behavioural sciences (1988), McGraw-Hill, Boston, MA
40. Swaiston T. Aripiprazole: A review of its use in schizophrenia and schizoaffective disorder. Drugs 64 (2004) 1715-1736
41. Tamminga C.A., and Carlsson A. Partial dopamine agonists and dopaminergic stabilizers in the treatment of psychosis. Current Drug Targets-CNS & Neurological Disorders 1 (2002) 141-147
42. Tandon R., Marcus R.N., Stock E.G., Riera L.C., Kostic D., Pans M., et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad effectiveness trial with aripiprazole (BETA). Schizophrenia Research 84 (2006) 77-89
43. Travis M.J., Burns T., Dursun S., Fahy T., Frangou R., Gray R., et al. Aripiprazole in schizophrenia: Consensus guidelines. International Clinical Practice 59 (2005) 485-495
44. Volavka J., Czobor P., Citrome L., McQuade R.D., Carson W.H., Kostic D., et al. Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: Data from 5 double-blind studies. Journal of Clinical Psychiatry 66 (2005) 1362-1366
45. Weiden P.J., Aquila R., Dalheim L., and Standard J.M. Switching antipsychotic medications. Journal of Clinical Psychiatry 58 (1997) 63-72
46. Wilson M. DSM-III and the transformation of American psychiatry: A history. American Journal of Psychiatry 150 (1993) 399-410